Amgen Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Amgen Inc. stock analysis AMGN overview
Slightly Bullish +25

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Amgen (AMGN), Apogee Therapeutics (APGE) and Gilead Sciences (GILD)

📈 Scotiabank analyst Louise Chen upgraded Amgen to Buy with a $385 price target, suggesting 10.8% upside from recent trading levels.

⚖️ The current consensus rating for Amgen is Moderate Buy, reflecting an average price target of $366.70 against the company’s closed price of $349.77.

🧬 TD Cowen maintained a Buy rating on Amgen with a higher $420 price target in a March 11 report.

⚠️ Truist Financial analyst Danielle Brill maintained a Hold rating on Apogee Therapeutics, citing current share prices of $79.24.

📊 Despite the Hold, Apogee retains a Strong Buy consensus with an average price target of $120.60, implying 56% upside potential.

⚠️ TipRanks reiterated a Hold rating on Apogee Therapeutics with a more conservative $64 price target in recent coverage.

🏥 Truist analyst Gregory Renza initiated a Buy rating on Gilead Sciences based on March 25 market data.

🎯 Gilead Sciences enjoys a Strong Buy consensus rating with an average price target of $158, representing 13% upside from current levels.

💰 Jefferies initiated coverage on Gilead in early March, assigning a Buy rating and a higher $180 price target.

🏛️ Amgen recently expanded its oncology pipeline with a new Phase 1 study for AMG 436 in MSI-H/dMMR tumors.

📉 Vertex Pharmaceuticals saw its price target raised to $550 from $515 at Wells Fargo.

🔍 TipRanks analysts generally show varied success rates across these healthcare stocks, ranging from 46% to 51%.

Bullish Signals
  • Scotiabank analyst Louise Chen maintained a Buy rating on Amgen with a price target of $385.00, which represents potential upside from the current closing price of $349.77.
  • TD Cowen reiterated a Buy rating on Amgen and set a higher price target of $420.00, signaling strong confidence in the company's prospects.
  • The analyst consensus for Amgen is a Moderate Buy with an average price target of $366.70, indicating a 4.2% upside from current levels.
  • Apogee Therapeutics holds a Strong Buy analyst consensus with a price target of $120.60, representing a significant 56.0% upside from its current trading price of $79.24.
  • Truist Financial analyst Gregory Renza maintained a Buy rating on Gilead Sciences and set a positive outlook for the stock.
  • Gilead Sciences has a Strong Buy analyst consensus with an average price target of $158.00, offering a 13.1% upside potential.
  • Jefferies initiated coverage on Gilead Sciences with a Buy rating and a robust price target of $180.00, demonstrating renewed institutional interest.
  • Analyst Danielle Brill is recognized as a 5-star analyst with an impressive 51.8% success rate, adding credibility to her Hold recommendation for Apogee Therapeutics.
Risk Factors
  • Analyst consensus on Apogee Therapeutics shows conflicting signals with a Hold rating from Truist Financial alongside a Strong Buy consensus, creating uncertainty despite a 56.0% upside target.
  • A report from TipRanks – xAI reiterated a Hold rating on Apogee Therapeutics with a $64.00 price target, which is significantly lower than the $120.60 consensus and current trading levels.
Full Analysis
Analysts have released mixed opinions on three healthcare stocks, with Scotiabank analyst Louise Chen maintaining a Buy rating on Amgen (AMGN) while assigning a price target of $385.00; the company's shares closed at $349.77 as of last Monday. According to TipRanks.com, Chen is a 4-star analyst with an average return of 3.5% and a 47.3% success rate. The current analyst consensus for Amgen is Moderate Buy with an average price target of $366.70, representing a 4.2% upside from current levels. TD Cowen previously maintained a Buy rating on the stock with a price target of $420.00 in a report issued on March 11. For Apogee Therapeutics (APGE), Truist Financial analyst Danielle Brill maintained a Hold rating on the company, which saw shares close last Monday at $79.24. TipRanks notes that Brill is a 5-star analyst with an average return of 13.7% and a 51.8% success rate. Despite the Hold rating from Truist, the overall analyst consensus for Apogee Therapeutics is Strong Buy, with a price target consensus of $120.60, implying a 56.0% upside from current levels. Additionally, TipRanks reiterated a Hold rating on the stock yesterday with a price target of $64.00. Truist Financial analyst Gregory Renza maintained a Buy rating on Gilead Sciences (GILD) today; the company's shares closed last Monday at $137.34. Renza is a 5-star analyst with an average return of 17.8% and a 46.4% success rate, focusing on the Healthcare sector. The overall analyst consensus for Gilead Sciences is Strong Buy, with a price target consensus of $158.00, representing a 13.1% upside. Jefferies initiated coverage on March 10 with a Buy rating and a price target of $180.00. Other recent developments mentioned in related healthcare news include Amgen expanding its oncology pipeline with a new Phase 1 study for AMG 436, Vertex Pharmaceuticals having its price target raised to $550 by Wells Fargo, and Amgen seeing its price target raised to $390 at Wells Fargo.